Evolution of therapy for chronic hepatitis B: progressing from the simple to the complex.

@article{Feld2007EvolutionOT,
  title={Evolution of therapy for chronic hepatitis B: progressing from the simple to the complex.},
  author={Jordan J Feld and Marc G Ghany},
  journal={Annals of internal medicine},
  year={2007},
  volume={147 11},
  pages={806-8}
}
In the past decade, physicians treating chronic hepatitis B have gained the luxury of choice. The U.S. Food and Drug Administration has approved 6 drugs for treating chronic hepatitis B (listed in order of approval date): interferon-2b, lamivudine, adefovir, entecavir, pegylated interferon-2a, and telbivudine (1). The introduction of nucleoside and nucleotide analogues has revolutionized therapy for chronic hepatitis B. Unlike interferon, these agents are orally administered, well tolerated… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 22 references

BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B

  • TT Chang, RG Gish, R de Man, A Gadano, J Sollano, YC Chao
  • N Engl J Med
  • 2006

Similar Papers

Loading similar papers…